Company Profile

Ibere Pharmaceuticals is a blank check company. The Company is created for the purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company focuses on healthcare sector. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

15/22/15	Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
13/22/13	Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
16/22/16	Ibere Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
01/22/01	Ibere Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021	CI
31/22/31	Ibere Pharmaceuticals Auditor Raises 'Going Concern' Doubt	CI
13/21/13	Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
24/21/24	Certain Class B Ordinary Shares of Ibere Pharmaceuticals are subject to a Lock-Up Agreement Ending on 24-AUG-2021.	CI
17/21/17	Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
02/21/02	Ibere Pharmaceuticals announced that it has received $4.835 million in funding	CI
26/21/26	Ibere Pharmaceuticals has completed an IPO in the amount of $120 million.	CI
25/21/25	Ibere Pharmaceuticals announced that it expects to receive $4.835 million in funding	CI
08/21/08	Ibere Pharmaceuticals has filed an IPO in the amount of $100 million.	CI

04/21/04	Ibere Pharmaceuticals : Letter dated August 4, 2021 from Marcum LLP (Form 8-K)	PU
29/21/29	Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report	PR
29/21/29	Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report (Form 8-K)	PU

Manager	Title	Age	Since
Osagie Imasogie CEO	Chief Executive Officer	64	-
Lisa Gray DFI	Director of Finance/CFO	61	-
Zoltan Kerekes COO	Chief Operating Officer	60	-

Director	Title	Age	Since
Osagie Imasogie CHM	Chairman	64	-
Lisa Gray BRD	Director/Board Member	61	-
Zoltan Kerekes BRD	Director/Board Member	60	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/03/21	Louis J. Vollmer	Buy	Director	10,000	0.0833%
25/02/21	Pipv Capital	Other	Company	33,50,000	-
25/02/21	Louis J. Vollmer	Other	Director	25,000	0.8333%

Ibere Pharmaceuticals Share Price

Stocks

IBER

KYG468431013

Investment Holding Companies

Latest news: Ibere Pharmaceuticals

Press Releases: Ibere Pharmaceuticals

Quotes and Performance

Managers and Directors: Ibere Pharmaceuticals

Latest insider transactions

Shell Companies

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IBERE PHARMACEUTICALS	-0.29%	+0.10%	-	-	18Cr
CHURCHILL CAPITAL CORP XI	+2.32%	-6.16%	-	-	67Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.15%	+0.20%	-	-	65Cr
BAIN CAPITAL GSS INVESTMENT CORP.	0.00%	-0.48%	-	-	60Cr
CANTOR EQUITY PARTNERS IV, INC.	0.00%	-0.15%	+0.98%	-	59Cr
CENTIEL AG	+0.67%	-14.53%	+294.74%	-73.45%	58Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.09%	-0.98%	+3.34%	-	55Cr
NEW AMERICA ACQUISITION I CORP.	+0.05%	-0.20%	-	-	50Cr
ARES ACQUISITION CORPORATION III	+0.50%	+0.30%	-	-	50Cr
Average	+0.37%	-2.04%	+99.69%	-73.45%	58.05Cr
Weighted average by Cap.	+0.46%	-2.16%	+101.32%	-73.45%